GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Pharmaceutical Group Co Ltd (SHSE:600664) » Definitions » Capex-to-Operating-Income

Harbin Pharmaceutical Group Co (SHSE:600664) Capex-to-Operating-Income : 0.06 (As of Mar. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Harbin Pharmaceutical Group Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Harbin Pharmaceutical Group Co's Capital Expenditure for the three months ended in Mar. 2024 was ¥-14.75 Mil. Its Operating Income for the three months ended in Mar. 2024 was ¥250.48 Mil.

Hence, Harbin Pharmaceutical Group Co's Capex-to-Operating-Income for the three months ended in Mar. 2024 was 0.06.


Harbin Pharmaceutical Group Co Capex-to-Operating-Income Historical Data

The historical data trend for Harbin Pharmaceutical Group Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harbin Pharmaceutical Group Co Capex-to-Operating-Income Chart

Harbin Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 - 0.13 0.14 0.11

Harbin Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.07 0.08 0.19 0.06

Competitive Comparison of Harbin Pharmaceutical Group Co's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Harbin Pharmaceutical Group Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harbin Pharmaceutical Group Co's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Harbin Pharmaceutical Group Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Harbin Pharmaceutical Group Co's Capex-to-Operating-Income falls into.



Harbin Pharmaceutical Group Co Capex-to-Operating-Income Calculation

Harbin Pharmaceutical Group Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-86.535) / 760.251
=0.11

Harbin Pharmaceutical Group Co's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-14.745) / 250.477
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harbin Pharmaceutical Group Co  (SHSE:600664) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Harbin Pharmaceutical Group Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Harbin Pharmaceutical Group Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Harbin Pharmaceutical Group Co (SHSE:600664) Business Description

Traded in Other Exchanges
N/A
Address
Xi'an Street West, People 's Development Zone Baoan Road South, Heilongjiang Province, Harbin, CHN, 150018
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
Executives
Lin Guo Ren senior management
Wang Hai Sheng senior management
Liu Bo senior management
Meng Xiao Dong senior management
Xu Hai Ying Directors, senior managers
Liang Chen senior management
Wang Peng Hao senior management
Xiao Qiang senior management
Wei Shuang Ying senior management
Zhou Xing senior management
Bian Ke Supervisors
Sha Mei senior management
Jian Shi Hui Zhu Xi Supervisors
Wang Zhi Fu Supervisors
Jiang Lu Director

Harbin Pharmaceutical Group Co (SHSE:600664) Headlines

No Headlines